International Liver Surgery Outcomes Study

Overview

This study was to designed to measure the true worldwide practice of liver surgery and associated outcomes by recruiting multiple international centres, committing to consecutive patient registration per surgeon and undergo rigorous data validation. It is hoped that these data will provide a more appropriate guide to inform surgeons and patients to assess which level of complexity should be routinely offered for high tumour burden and anatomically difficult scenarios.

Full Title of Study: “International Study on the Outcomes of Liver Surgery – LiverGroup.Org”

Study Type

  • Study Type: Observational [Patient Registry]
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: March 31, 2020

Detailed Description

Liver surgery was associated with at least 10% mortality in the 1970's. The safety of liver surgery has dramatically improved since with a mortality of now around 1-2%. Individual centres postulate that a perioperative mortality close to 0% should be the standard of major liver resection. Despite these claims, epidemiological studies showed a mortality rate of 6%. Outcomes in liver surgery are likely influenced by indications, complexity, centre and surgeon skills, equipment, centre and surgeon experience. The aim of LiverGroup.org is to develop an international data set on the outcomes of liver resections among a large number of international surgeons. The 'collaborative' model for 'snapshot' clinical audit is now well established and such research is a novel approach for assessing current practice in a short period of time. The primary objective of the study is to provide a verified record of the true perioperative morbidity and mortality of a representative set of liver surgeons worldwide in 2019. Secondary objectives include risk factors for mortality and morbidity using multivariable regression models. Any surgeon performing liver resections is eligible to participate in LiverGroup.org. All consecutive cases will be included and there are no minimum patient numbers per centre. Liver transplantation is excluded. There will be 3 months of prospective patient enrolment and 3 months follow up within the 12-month frame, January to December 2019. All liver resections, all indications, as well as all co-morbidities will be included. Liver transplantation, imaging-guided ablations and liver biopsies are excluded.

Interventions

  • Procedure: Liver surgery
    • All indications (including benign and living donor resections), all co-morbidities, open, laparoscopic or robotic, single wedge resections to extended liver resections, single or two-stage hepatectomies, procedures with liver volume enhancement such as portal vein embolization (PVE), portal vein ligation (PVL), “Associating Liver Partition and Portal vein Ligation for Staged hepatectomy” (ALPPS), resections involving cold perfusion (ex-situ and ante-situ)

Arms, Groups and Cohorts

  • Liver surgery
    • Any type of liver surgery

Clinical Trial Outcome Measures

Primary Measures

  • Mortality rate
    • Time Frame: From operation until 90 days postoperatively
    • Death

Secondary Measures

  • Complication rate
    • Time Frame: From operation until 90 days postoperatively
    • Postoperative complications according the the Clavien-Dindo classification, the “liver Failure, Ascites, Bile leakage, Infection, Bleeding” (FABIB) liver specific classification, as well as the novel Comprehensive Complications Index® (CCI® ).
  • Liver failure rate
    • Time Frame: From operation until 90 days postoperative
    • Posthepatectomy liver failure will be assessed according to the FABIB Classification, the “International Study Group of Liver Surgery” (ISGLS) criteria as well as the 50-50 criteria up to 90 days postoperatively.
  • Hospital stay
    • Time Frame: From operation until discharge from the hospital or up to 90 days postoperatively.
    • The length of hospital stay is defined as the duration of hospitalization from the day of the operation until the day of discharge from the hospital.
  • Re-hospitalisation rate
    • Time Frame: From operation until 90 days postoperatively
    • Readmission to any hospital

Participating in This Clinical Trial

Inclusion Criteria

  • All indications (including benign and living donor resections) – All co-morbidities – Open, laparoscopic or robotic – Single wedge resections to extended liver resections – Single or two-stage hepatectomies – Procedures with liver volume enhancement such as PVE, PVL, ALPPS. – Resections involving cold perfusion (ex-situ and ante-situ) – There are no exclusion criteria as related to indication, age or comorbidities. Exclusion Criteria:

  • Liver transplantation – Imaging-guided liver ablation techniques alone – Liver biopsies

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Royal Free Hospital NHS Foundation Trust
  • Collaborator
    • Hospital Miguel Servet
  • Provider of Information About this Clinical Study
    • Principal Investigator: Dimitri Raptis, Senior Clinical Fellow – Royal Free Hospital NHS Foundation Trust
  • Overall Official(s)
    • Massimo Malagò, MD, PhD, Principal Investigator, Royal Free Hospital, London, UK

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.